D&A at other companies
Other financials
Where this comes from
Reported directly by Ionis Pharmaceuticals in its filing.
Tagged under the XBRL concept us-gaap:AmortizationOfIntangibleAssets.
The official record: Ionis Pharmaceuticals’s 10-Q, filed April 29, 2026, on SEC EDGAR. View the filing →
Ask your AI about Ionis Pharmaceuticals's d&a.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Ionis Pharmaceuticals's D&A?
- Ionis Pharmaceuticals (IONS) reported D&A of $661K in Q1 2026.
- How has Ionis Pharmaceuticals's D&A changed year-over-year?
- Ionis Pharmaceuticals's D&A increased by 13.6% year-over-year, from $582K to $661K.
- What does D&A mean?
- The non-cash cost of using up physical and intangible assets over time.
- How do you interpret D&A?
- High levels relative to revenue may indicate a capital-intensive business model or significant past acquisition activity.
- How does D&A compare across companies?
- Universal metric; essential for calculating EBITDA and comparing operational efficiency across industries.